Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 4, 2010 (13 weeks)
Business Overview: Illumina is a leading developer of integrated systems for genetic analysis, serving sequencing, genotyping, and gene expression markets. The company operates primarily in one reportable segment (Life Sciences) as the Diagnostics unit activity remains below the 10% threshold for separate reporting.
Key Financial Metrics
| Metric (in thousands) | Q1 2010 | Q1 2009 |
|---|---|---|
| Total Revenue | $192,131 | $165,757 |
| Gross Profit | $132,178 | $110,065 |
| Gross Margin | 69% | 66% |
| Net Income | $21,208 | $18,811 |
| Diluted EPS | $0.16 | $0.14 |
| Operating Cash Flow | $55,364 | $50,748 |
| Cash & Short-term Investments | $747,980 | $693,527 |
| Long-term Debt (Current Portion) | $295,404 | $290,202 |
Note: Debt figures represent the carrying value of convertible senior notes, which are classified as current liabilities due to the cash settlement option.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 16% year-over-year. Product revenue rose 11% ($173.7M vs $156.2M), while Service and other revenue surged 93% ($18.5M vs $9.6M).
- Product Mix Shift: Sequencing consumable revenue grew 84% ($20.3M increase) driven by an expanding installed base. Conversely, microarray consumable revenue declined $9.4M due to lower sales of whole-genome genotyping arrays, partially offset by focused content arrays.
- Instrument Sales: Instrument revenue increased 13% ($6.8M), driven by the launch of the HiSeq 2000 sequencing system and the transition from Genome Analyzer II to IIx.
- Operating Expenses: Total operating expenses increased 24% ($94.0M vs $75.6M). R&D expenses rose 33% due to personnel growth and project supplies; SG&A increased 17% primarily due to personnel expansion.
- Tax Provision: The effective tax rate increased to 36.4% from 35.9%, largely due to the expiration of the federal R&D credit at the end of 2009.
Outlook, Risks, and Management Commentary
- HiSeq 2000 Launch: The company began shipping the HiSeq 2000 in Q1 2010, creating significant demand and record backlog levels. Management expects to ramp manufacturing capacity to meet demand by the end of Q2 2010.
- Microarray Outlook: A slowdown in microarray sales is expected to persist until new arrays featuring rare variant content from the 1000 Genomes Project are launched later in 2010.
- Recovery Act Impact: Approximately $21.0M in orders were directly related to the American Recovery and Reinvestment Act of 2009. Management anticipates a pipeline of opportunities from these grants throughout 2010.
- Liquidity & Auction Rate Securities: The company holds $54.5M in illiquid auction rate securities. A settlement with UBS allows Illumina to sell these at par between June 30, 2010, and July 2, 2012. These are classified as short-term investments based on the intent to exercise this option.
- Convertible Notes: The company has $390M principal of 0.625% convertible senior notes due in 2014. $10M of notes were converted in Q1 2010.
- Risks: Key risks include the ability to commercialize new technologies, manufacturing robustness, and potential reductions in funding from primary customers (e.g., NIH grants).
Investor Verification Checklist
- Backlog Realization: Verify if the record backlog driven by the HiSeq 2000 translates into revenue in Q2 and Q3 as manufacturing capacity ramps up.
- Auction Rate Securities: Monitor the status of the UBS settlement agreement and the liquidity of the $54.5M in auction rate securities.
- Microarray Recovery: Track the launch timeline and market reception of new microarrays with 1000 Genomes Project content to confirm the anticipated recovery in that segment.
- Tax Rate Volatility: Confirm the retroactive application of the federal R&D tax credit for fiscal 2010 to assess future effective tax rates.
- Debt Conversion: Monitor stock price relative to the $21.83 conversion price of the convertible notes to assess potential dilution or cash settlement obligations.